- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00588458
The Value of CT Cholangiography in Primary Sclerosing Cholangitis
April 27, 2015 updated by: Mayo Clinic
Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis
The reason for this study is to see if a new radiologic technique called computerized tomographic cholangiography (CT cholangiography) could be helpful to demonstrate the bile ducts features and measure the amount of space of bile duct canals that should be filled with bile fluid.
It may be useful to find out how well these findings correlate with the previously known clinical predictors in term of the clinical outcomes that will happen in the future for patients with primary sclerosing cholangitis (PSC).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Prognostic models, which have been produced based on clinical, histological and biochemical feature, are useful in predicting survival and determining timing for liver transplantation.
Preliminary feasibility studies in patients with PSC using high resolution CT with a contrast agent (CT cholangiography), has shown excellent depiction of bile ducts.
CT cholangiography also has the potential to allow quantification of intraductal volume by using sophisticated computer programs.
This assessment may be an important clinical feature to assess disease severity and progression.The information about cholangiographic features could be important for therapeutic decisions (e.g., in determining the usefulness of balloon dilatation or stenting for a dominant extrahepatic duct stricture), for counseling patients, and for therapeutic trials in stratifying patients and assessing efficacy of treatment.
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult males or females, age 18-70 (inclusive) with suspected PSC.
- Serum carbohydrate antigen 19-9 (CA19-9) level in normal range (obtained within the previous year), or if greater than normal, the patient requires a negative cytologic or histologic evidence for cholangiocarcinoma within prior 3 months.
- Sexually active female patients of childbearing potential must be evaluated for pregnancy. A pregnancy test obtained at entry prior to the initiation of treatment must by negative. Female patient must not be breast-feeding.
- Renal function: a creatinine less than 2.0 mg/dL or a diabetic patient with a creatinine less than 1.5 mg/dL.
Exclusion Criteria:
- Evidence of cholangiocarcinoma
- Pregnancy or breast feeding
- History of allergy to iodinated contrast agents or morphine
- Renal impairment as defined as known renal disease, a creatinine higher than 2.0 mg/dL or a diabetic patient with a creatinine higher than 1.5 mg/dL.
- Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study such as significant cardiovascular dysfunction or chronic obstructive pulmonary disease requiring specific therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: single arm
All patients with PSC in will have CT cholangiography.
|
Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval.
Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization.
Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion.
The test scan will consist of 10 mm thick image obtained through the mid liver.
If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts.
The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the correlation between baseline characteristics of bile ducts and intraductal volume of the biliary tree by CT cholangiography and MELD score and the Mayo risk score in patients with PSC.
Time Frame: baseline
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the correlation between change in characteristics of bile ducts and intraductal volume of the biliary tree by CT cholangiography and change in MELD score and the Mayo risk score after 2-years of follow-up as compared with baseline.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Phunchai Charatcharoenwitthaya, M.D., Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (ANTICIPATED)
November 1, 2008
Study Completion (ANTICIPATED)
February 1, 2009
Study Registration Dates
First Submitted
December 26, 2007
First Submitted That Met QC Criteria
December 26, 2007
First Posted (ESTIMATE)
January 8, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
April 28, 2015
Last Update Submitted That Met QC Criteria
April 27, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-002976 0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sclerosing Cholangitis
-
Medical University of WarsawNational Science Centre, PolandRecruitingPrimary Sclerosing Cholangitis (PSC)Poland
-
Mayo ClinicActive, not recruiting
-
Cascade Pharmaceuticals, IncCovanceCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
HighTide Biopharma Pty LtdCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy
-
Mirum Pharmaceuticals, Inc.CompletedPrimary Sclerosing Cholangitis (PSC)United States, United Kingdom, Canada
-
Mayo ClinicCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
Gilead SciencesCompletedPrimary Sclerosing Cholangitis (PSC)United States, Belgium, Canada, Germany, United Kingdom, Italy, Spain, Denmark, Netherlands, Sweden
-
Boston Scientific CorporationCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada, Netherlands, Norway
-
Brigham and Women's HospitalCompletedSclerosing CholangitisUnited States
Clinical Trials on CT cholangiography
-
Heidelberg UniversityUnknownCholangiographyGermany
-
Jyväskylä Central HospitalCompletedAcute CholecystitisFinland
-
Theodor Bilharz Research InstituteCompletedLaparoscopic Cholecystectomy | Gall Stone Disease | Common Bile Duct Stones. | Biliary Tract AnatomyEgypt
-
Hvidovre University HospitalZealand University Hospital; Hillerod Hospital, DenmarkWithdrawn
-
Royal Brompton & Harefield NHS Foundation TrustCompletedCommon Bile Duct StonesUnited Kingdom
-
Jyväskylä Central HospitalCompleted
-
Hannover Medical SchoolGerman Research FoundationTerminatedSecondary Sclerosing CholangitisGermany
-
Hospital Son EspasesUnknownCholecystitis/Cholelithiasis
-
Jyväskylä Central HospitalCompleted
-
Centre Hospitalier Universitaire, AmiensRecruitingCholecystitis, Acute | Lithiasis | CholangiopathyFrance